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A B S T R A C T
Background: Patients with psychiatric disorders (depression, anxiety) are more likely to have poor health be-
haviours, including higher smoking and lower physical activity (PA) levels. Smoking is a major risk factor for
Chronic Obstructive Pulmonary Disease (COPD), and PA is critical for COPD management. However, no studies
have assessed associations between psychological distress and these behaviours among patients with vs without
COPD. This is a sub-analysis of the CanCOLD study that assessed the relationships between psychological dis-
orders (depression, anxiety) and poor health behaviours (smoking, PA).
Methods: 717 COPD and 797 matched non-COPD individuals from the CanCOLD study, completed the Hospital
Anxiety Depression Scale (HADS) to assess anxiety and depression. Smoking behaviour was self-reported pack-
years smoking. The CHAMPS PA questionnaire determined calorific expenditure as a PA measure. Regressions
determined relationships between anxiety/depression and health behaviours, adjusting for age, sex, BMI, GOLD
stage and COPD status.
Results: Across the whole sample, we observed relationships between depression (β= 1.107 ± 0.197;
95%CI=0.691–1.462; p < .001) and anxiety (β=0.780 ± 0.170; 95%CI=0.446–1.114; p < .001) and
pack years. Higher depression (β=−0.220 ± 0.028; 95%CI=−0.275 to −0.165; p < .001) and anxiety
(β=−0.091 ± 0.025; 95%CI=−0.139 to −0.043; p < .001) scores were related to lower PA. These asso-
ciations were comparable across COPD and non-COPD patients.
Conclusions: Results showed that higher levels of anxiety and depression were related to higher cumulative
smoking and lower levels of PA in patients with and without COPD, suggesting symptoms of psychological
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distress is similarly associated with poorer health behaviours in COPD and non-COPD individuals. Future studies
need to determine if treating symptoms of psychological distress can improve health behaviours and outcomes in
this population.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by
chronic, not completely reversible airway obstruction, and is predicted
to become the 3rd leading cause of death by 2030 [1]. COPD and
subsequent exacerbations are associated with important health and fi-
nancial burdens including frequent hospitalizations, increased medi-
cation usage and functional physical impairment [2,3]. Additionally,
COPD is associated with significant psychological consequences. Stu-
dies have shown that there is an increased prevalence of psychological
distress among patients with COPD, with up to 55% of patients suf-
fering from a clinical diagnosis of anxiety and/or depression [4].
The presence of significant psychological distress has important
implications for the adoption and maintenance of healthy behaviours.
Non-COPD patients with psychiatric disorders (such as depressive and
anxiety disorders) typically have worse health behaviours, including
higher rates of smoking [5,6] and lower levels of physical activity (PA)
[7]. These poor health behaviours have important consequences for
individuals in general and those with COPD. The most important causal
factor of COPD is smoking, with greater cumulative smoking leading to
an increase likelihood of chronic airway obstruction [8]. Additionally,
exercise is a cornerstone of pulmonary rehabilitation, and engaging in
regular PA has been linked to improved symptoms, quality of life and
lower risk of COPD exacerbation [9,10]. Though studies have examined
the relationship between psychological distress and health behaviours
in patients with asthma [11], no studies have assessed the association
between psychological distress and health behaviours among COPD
patients or those at high risk for developing COPD.
This aim of this study was to assess relationships between levels of
psychological distress (depression, anxiety) and poor health behaviours
(smoking, reduced PA) in individuals with and at risk for COPD in the
Canadian Cohort Obstructive Lung Disease (CanCOLD) study. We hy-
pothesized that higher levels of depression and anxiety would be as-
sociated with higher cumulative smoking levels and lower levels of PA,
and that these relationships would be stronger in patients with versus
without COPD.
2. Methods and materials
2.1. Sample
Our sample of participants was taken from the baseline assessment
of participants in the CanCOLD study. CanCOLD is a pan-Canadian,
prospective longitudinal cohort study, which consists of balanced co-
horts of COPD (classified as GOLD ≥2 and GOLD 1) (Total N=717)
and non-COPD participants (Total N=797), who have normal post
bronchodilator spirometry (ever smoker for those at-risk and never-
smoker for the healthy controls). Details regarding the full study design,
protocol and ethical approval can be found and described in full detail
elsewhere [12].
2.2. COPD characterisation
Questionnaires determined sociodemographic information and
COPD-related health measures such as exacerbation incidence and ex-
posure to fumes, vapours and dust. Spirometry and assessments of lung
function were conducted according to standard techniques, as described
elsewhere [12]. GOLD 1–4 classification was used to determined dis-
ease severity based on post-bronchodilator airflow obstruction [13].
Subjects with a FEV1/FVC post bronchodilator< 0.7 were determined
to have COPD (N=717); those with a FEV1/FVC post bronchodi-
lator > 0.70 were considered non-COPD (N=797). Further, severity
of COPD was define as GOLD 1, 2 or 3 [14].
2.3. Assessment of psychological distress
Depression and anxiety were assessed using the Hospital Anxiety
and Depression Scale (HADS) [15]. The HADS is a 14-item scale that
yields was used to determine the level of depressive (HADS-D) and
anxiety (HADS-A) symptoms. Scores range from 0 to 21 for each sub-
scale, with higher scores denoting higher levels of depression and an-
xiety. The HADS demonstrates excellent internal consistency (HADS-
A=0.83; HADS-D=0.82) and test-retest reliability (HADS-A=0.89;
HADS-D=0.92) [15,16].
2.4. Assessment of smoking behaviours
Smoking behaviours were assessed by self-reported questionnaire to
determine smoking status and smoking volume. Smoking status was
classified as “Ever-smoker” and “Never-smoker”. Smoking volume was
determined by smoking pack years, per the standard definition of
multiplying the number of packs of cigarettes smoked per day by the
number of years the person has smoked [17].
2.5. Assessment of physical activity (PA)
Levels of PA were determined by the Community Healthy Activities
Model Program for Seniors (CHAMPS) questionnaire [18], and has been
used cross-culturally in Canada [19]. The questionnaire was chosen
given its age appropriateness for the sample (mean age 66.71 ± 9.83).
The CHAMPS is a 40-item questionnaire that assesses both the weekly
frequency and calorific expenditure associated with physical activities
in an older population [18]. The CHAMPS allows for determination of 4
categories of activity: 1) the caloric expenditure per week of activities
of a moderate intensity or greater (MET value ≥3.0); 2) the caloric
expenditure per week of all activities (including lower intensity ac-
tivity); 3) the weekly frequency of activities of a moderate intensity or
greater (MET value ≥3.0); 4) the weekly frequency of all activities
Abbreviations
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(including lower intensity activity). This was then used to determine
levels of all PA and moderate PA only. The CHAMPS has a correlation
between frequency and caloric expenditure of 0.73 for moderate in-
tensity PA, and of 0.55 for all activity [18].
2.6. Statistical analysis
Analyses were undertaken using SAS version 9.4. Significance was
set at p < .05. Occasional missing data are reflected in the degrees of
freedom. One-way general linear models and χ2 analyses were used to
Table 1
Sample characteristics.
Variable Mean (SD) or N (%) No COPD (N=797) COPD (N=717) F/Χ2 p Missing N
Sex (Women) 662 (46.23) 362 (50.28) 280 (41.67) 10.37 .0013 40
Age (years) 66.71 (9.83) 66.05 (9.55) 67.46 (10.08) 7.21 .0074 40
BMI (kg/m2) 27.57 (5.03) 27.82 (5.22) 27.20 (4.81) 5.38 .0205 44
Years of School 15.57 (3.67) 15.79 (3.43) 15.37 (3.92) 4.46 .0348 43
Smoking Pack Years 18.25 (23.31) 12.29 (19.47) 24.24 (25.08) 99.11 < .0001 40
CHAMPS scores (Kilocalories/week), all activities 4.08 (3.12) 4.16 (3.24) 4.07 (3.02) 0.32 .57 40
CHAMPS scores (Kilocalories/week), moderate activities 2.27 (2.44) 2.34 (2.54) 2.26 (2.37) 0.40 .53 40
Post-bronchodilator FEV1 (L) 2.52 (0.81) 2.72 (0.78) 2.30 (0.78) 101.98 < .0001 40
Post-bronchodilator FVC (L) 3.65 (1.08) 3.54 (1.02) 3.76 (1.12) 13.74 .0002 40
HADS - Anxiety Score (HADS-A) 3.98 (3.24) 4.08 (3.32) 3.84 (3.13) 1.86 .17 47
Proportion with HADS-A≥8 128 (8.94) 68 (9.44) 54 (8.04) 0.86 .35 40
HADS - Depression Score (HADS-D) 2.84 (2.74) 2.78 (2.84) 2.82 (2.54) 0.10 .75 46
Proportion with HADS-D≥8 59 (4.12) 33 (4.58) 23 (3.42) 1.21 .27 40
Occupational Status 4.04 .54 41
Retired 865 (60.53) 423 (58.75) 420 (62.59)
Full time 303 (21.20) 162 (22.50) 132 (19.67)
Part time 173 (12.11) 93 (12.92) 75 (11.18)
Disability Insurance 38 (2.66) 20 (2.78) 17 (2.53)
Unemployed Insurance 13 (0.91) 6 (0.83) 7 (1.04)
Home 37 (2.59) 16 (2.22) 20 (2.98)
Education Level 14.24 .0066 41
Primary 23 (1.61) 7 (0.97) 15 (2.24)
Middle 47 (3.28) 16 (2.22) 31 (4.62)
High 261 (18.24) 117 (16.25) 133 (19.82)
Some college 366 (25.58) 193 (26.81) 163 (24.29)
University 734 (51.29) 387 (53.75) 329 (49.03)
Smoking status 48.17 < .0001 40
Never 456 (38.13) 336 (46.67) 195 (29.02)
Ex-smokers 659 (46.02) 299 (41.53) 350 (52.08)
Current smokers 227 (15.85) 85 (11.81) 127 (18.90)
Medical characteristics and history
GOLD status 1393.00 < .0001 40
Normal 336 (24.14) 336 (46.67) 0 (0)
At risk 384 (27.59) 384 (53.33) 0 (0)
GOLD1 373 (26.80) 0 (0) 373 (55.51)
GOLD2 259 (18.61) 0 (0) 259 (38.54)
GOLD3 40 (2.87) 0 (0) 40 (5.95)
Physician diagnosed asthma 334 (23.32) 116 (16.11) 210 (31.25) 44.42 < .0001 40
Cardiovascular Disease diagnosis 219 (15.29) 99 (13.75) 110 (16.37) 1.87 .17 40
Diabetes diagnosis 144 (10.06) 74 (10.28) 63 (9.38) 0.32 .57 40
Any musculoskeletal disorder 477 (33.31) 236 (32.78) 227 (33.78) 0.16 .69 40
Chronic Bronchitis 193 (13.49) 70 (9.74) 112 (16.67) 14.67 < .0001 41
Taking Short Acting Broncho Dilator (SABD) 57 (3.98) 9 (1.25) 47 (6.99) 29.70 < .0001 40
Taking Long Acting Beta-Agonists (LABA) or Long Acting Muscarinic Antagonists
(LAMA)
20 (1.40) 5 (0.69) 15 (2.23) 5.80 .0160 40
Taking Inhaled Corticosteroid (ICS) 89 (6.22) 35 (4.86) 51 (7.59) 4.46 .0346 40
Taking ICS combined with LABA/LAMA 167 (11.67) 32 (4.44) 129 (19.20) 73.95 < .0001 40
Regularly exposed to Dust during job 116 (8.11) 61 (8.47) 52 (7.74) 0.25 .62 40
Regularly exposed to Fumes during job 48 (3.36) 26 (3.61) 20 (2.98) 0.44 .50 40
Regularly exposed to Vapours during job 31 (2.17) 16 (2.22) 14 (2.08) 0.032 .86 40
Regularly exposed to Gases during job 23 (1.61) 14 (1.94) 8 (1.19) 1.27 .26 40
Experienced a COPD exacerbation during the past 12 months
Number of Exacerbations in last 12 months 68 (4.75) 19 (2.64) 45 (6.70) 14.92 .0049 40
0 1363 (95.25) 701 (97.36) 628 (93.45)
1 40 (59.70) 12 (1.67) 25 (3.72)
2 13 (19.40) 5 (0.69) 8 (1.19)
3 7 (10.45) 0 (0) 6 (0.89)
4 or more 7 (10.45) 2 (0.28) 5 (0.74)
Note: BMI = Body Mass Index; CHAMPS = Community Healthy Activities Model Program for Seniors; HADS = Hospital Anxiety Depression Scale; SABD = Short
Acting Broncho Dilator (SABD); LABA=Long Acting Beta-Agonists; LAMA=Long Acting Muscarinic Antagonists; ICS = Inhaled Corticosteroid; GOLD=Global
Initiative for Chronic Obstructive Lung Disease.
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compare baseline sociodemographic and clinical characteristics by
COPD group. Analysis of psychological distress symptoms (measured
continuously) per group (COPD risk [categorised as Never-smoker,
Ever-smoker, and COPD GOLD stage>1]; GOLD stage; and current
smoking status) were analysed using GLM, with Tukey post-hoc tests.
The relationships between psychological distress and smoking beha-
viour, and between psychological distress and PA were examined using
a series of linear regressions, which were adjusted for age, sex, body
mass index (BMI), GOLD stage and COPD group. For each health be-
haviour (smoking, PA), Model 1 examined the relationship to depres-
sion, Model 2 the relationship to anxiety. Analyses were conducted to
examine possible interactions between health behaviours and depres-
sion/anxiety levels and COPD group with Model 3 examining the in-
teraction between COPD group and depression level, and Model 4 ex-
amining the interaction between COPD group and anxiety level. Finally,
to determine if there was a difference in the impact of comorbid de-
pression and anxiety in individuals with and without COPD, a series of
3-way interactions were completed. Identical analyses were completed
as supplementary content to determine the impact of COPD risk group
(i.e., never smokers, ever smokers and GOLD Stage>1) on the above
behaviours.
3. Results
3.1. Sample characteristics
Sample characteristics are displayed in Table 1 for the whole sample
and for subjects with and without COPD. Across our sample, individuals
with COPD were more likely to be men, older, have a higher cumulative
exposure of smoking as measured by pack years, be former or current
smokers, have more COPD exacerbations in the previous year, a higher
rate of physician diagnosed asthma and chronic bronchitis, and greater
medication prescribed (both short-acting, long-acting and ICS) com-
pared to those without COPD (all p's < 0.05). Unsurprisingly, in-
dividuals with COPD also had worse spirometry profiles with lower
FEV1 and FVC recordings than in those without COPD (p's < 0.001).
There were no significant differences in the mean depression and an-
xiety scores between individuals with and without COPD.
We also explored the degree of depression and anxiety symptoms
within our sample (Table 2). These results showed that there were trend
effects of COPD risk on HADS-D (F=2.6, p = .074) and HADS-A
(F= 2.48, p= .084). There were main effects of GOLD stage for HADS-
D (F=5.84, p < .001) where post-hoc analysis showed elevated de-
pression symptoms in patients at GOLD Stage 3 compared to those at
GOLD stage 1 or 2 plus those who were not categorised as having a
GOLD score. No effect was observed for HADS-A (F= 1.44, p = .22).
There were main effects of current smoking status for both HADS-D
(F= 27.2, p < .001) and HADS-A (F=14.05, p < .001). For both of
these main effects the highest scores were observed in current smokers
(Table 2) and were significantly higher than scores for never and ever
(past) smokers (p's < 0.05). There were no differences in scores be-
tween never and ever smokers (p's > 0.05).
3.2. The relationships between depression, anxiety and health behaviours
3.2.1. Smoking (pack years)
As shown in Table 3, analyses revealed that there were positive
relationships between depressive symptoms and cumulative smoking as
measured by pack years (β=1.107 ± 0.197; 95%CI=0.691–1.462;
p < .001) where higher smoking volume was seen in patients with
higher depression symptoms. A similar relationship was seen between
levels of anxiety and smoking (β= 0.780 ± 0.170;
95%CI=0.446–1.114; p < .001) with higher levels of anxiety seen in
patients with higher smoking volume. As seen in Fig. 1, there were no
interactions between depressive symptoms and COPD group
(β=0.380 ± 0.413; 95%CI=−0.430–1.19; p = .358) or anxiety
symptoms and COPD group (β=0.558 ± 0.337;
95%CI=−0.102–1.218; p = .098). Supplemental analysis examining
the effects of COPD risk group mirrored the main findings, with the
exception of the interaction effects between depression and COPD risk
(β=0.609 ± 0.265; 95%CI= 0.089–1.129; p = .022) and between
anxiety and COPD risk (β=0.476 ± 0.217; 95%CI=0.050–0.901; p
= .029). However, given that COPD risk was determined based on
smoking status, these interaction effects were to be expected.
3.2.2. Physical activity
Analyses revealed that there were negative relationships between
depressive symptoms and all PA (β=−0.220 ± 0.028;
95%CI=−0.275 to −0.165; p < .001) where lower PA levels were
evident in subjects with higher depression symptoms. A similar re-
lationship between levels of anxiety and PA was apparent
(β=−0.091 ± 0.025; 95%CI=−0.139 to −0.043; p < .001) with
higher levels of anxiety seen in subjects with lower levels of PA. No
interactions were seen between COPD group and depression/anxiety
symptoms (Table 4; Fig. 2). Our analyses also showed negative asso-
ciations between depressive symptoms and moderate activity
(β=−0.176 ± 0.022; 95%CI=−0.219 to −0.134; p < .001)
where lower PA levels were evident in subjects with higher depression
symptoms. A similar relationship was also observed for anxiety
(β=−0.073 ± 0.019; 95%CI=−0.111 to −0.036; p < .001)
(Fig. 3). Again, no interactions were observed between COPD group and
depression or anxiety (Table 5). Supplemental analysis examining the
impact of COPD risk group yielded similar results as the main analysis.
3.3. Interactions between depression and anxiety and health behaviours
Further analysis was undertaken to examine the possible impact of
comorbid depression and anxiety on health behaviours. As can be seen
in Table 6 no depression by anxiety interactions was observed for pack
years (β=0.005 ± 0.045; 95%CI=−0.083–0.093; p = .91), all PA
(β=0.009 ± 0.006; 95%CI=−0.003–0.022; p = .15) or moderate
PA levels (β= 0.007 ± 0.005; 95%CI=−0.003–0.017; p = .15).
4. Discussion
We assessed the relationship between symptom levels of
Table 2
Group differences in depression and anxiety scores by level of COPD risk, GOLD
stage and Current smoking status.
HADS-D Score HADS-A Score
Level of COPD risk Main effect: F=2.6, p =
.0743
Main effect: F= 2.48, p=
.0844
Never smoker 2.54 ± 2.65 3.85 ± 3.14
At risk 2.99 ± 2.98 4.28 ± 3.47
COPD (GOLD >1) 2.82 ± 2.55 3.84 ± 3.13
GOLD stage Main effect: F=5.84,
p < .001
Main effect: F= 1.44, p=
.22
Never smoker 2.54 ± 2.65+ 3.85 ± 3.14
At risk 2.99 ± 2.98+ 4.28 ± 3.47
GOLD 1 2.61 ± 2.39+ 3.85 ± 3.26
GOLD 2 2.87 ± 2.39+ 3.76 ± 2.89
GOLD 3+ 4.50 ± 3.97 4.25 ± 3.45
Current smoking
status
Main effect: F=27.2,
p < .001
Main effect: F= 14.05,
p < .001
Never smoker 2.44 ± 2.47∗ 3.69 ± 2.99∗
Ever smoker 2.77 ± 2.61∗ 3.88 ± 3.20∗
Current smoker 4.00 ± 3.35 5.00 ± 3.71
Note: Scores presented as Mean ± SD.+indicates significantly different from
GOLD stage> 3, (p < .05); ∗indicates significantly different from current
smokers (p < .05).
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psychological distress (depression, anxiety) and poor health behaviours
(smoking and reduced PA) in individuals with or at risk for COPD in the
CanCOLD study. Our results showed that higher symptoms of depres-
sion and anxiety were related to higher smoking volume and lower
levels of PA. These relationships were observed in both COPD and non-
COPD individuals, and there was no interaction between depression
and anxiety on health behaviours. Our results mirror those in other
respiratory populations which demonstrate a relationship between
psychiatric disorders (i.e., depressive and anxiety) and poor health
behaviours (i.e., higher rates of smoking, lower level of leisure-time PA)
in patients with asthma [11,20]. However, to our knowledge, no studies
have assessed the association between symptom levels of psychological
distress and these health behaviours among patients with or at risk for
COPD.
Depressive and anxiety disorders have been linked with worse
COPD outcomes in previous studies; depression (as measured by the
HADS) was associated with an increased risk of symptom-based ex-
acerbations (51% increase), event-based exacerbations (56% increase),
and hospitalization (72% increase) compared with COPD patients who
were not depressed [21]. Given that our analysis shows that higher
symptoms of psychological distress are linked to health behaviours that
are important determinants of COPD risk (smoking) and management
(PA – which is the aim of pulmonary rehabilitation programs), this
study appears to highlight a possible mechanism linking high levels of
depression and anxiety to worse COPD outcomes.
Non-COPD patients with higher levels of depression and anxiety
typically have worse health behaviours than their non-psychiatric
counterparts, including higher rates of smoking [5,6] and lower levels
of PA [7]. Therefore, given the high prevalence of psychological distress
in patients with COPD [4], and the potential impact of these negative
mood states on smoking behaviours and PA levels, screening for psy-
chological distress and developing interventions that target these health
risk behaviours in this population may be important for improving
management and outcomes. High levels of anxiety and depression has
been linked to worse health behaviours across a variety of populations.
Smoking is linked to increases in emotional self-regulation to reduce
negative emotions [22–25], as evidenced by instances when smokers
engage in smoking when under periods of stress to help deal with the
stressful episode [26–30]. Patients with high psychological distress may
also be more vulnerable to addictive behaviours and addictive prop-
erties of smoking including nicotine [31,32]. This can be further ex-
acerbated by the psychological distress associated with physiological
withdrawal during quit attempts (or failed attempts to quit) smoking
[33], making it more difficult for to quit smoking, which further aug-
ments the risk of COPD [8]. Similarly, our study demonstrated that
symptoms of psychological distress were linked to lower levels of PA.
Continued engagement in regular bouts of PA requires sustained mo-
tivation and effort. In patients with depressive symptoms, lowered
motivation and lack of energy are key symptoms [34], which may be a
mechanism through which higher levels of depressive symptoms dis-
tress are linked to lower PA levels. Importantly, failure to engage in
regular PA may be a proxy for lack of motivation or social functioning,
which may then subsequently lead to depression [35]. In patients with
high anxiety symptomology, there may be the presence of exaggerated
fears of negative consequences of PA/exercise, including symptoms that
are specific to PA such as increased fatigue, pain, breathlessness,
Table 3
Impact of depression and anxiety on smoking behaviours.
MAIN EFFECTS: Pack Years INTERACTION EFFECTS: Pack Years
Model 1 β± SE 95%CI p Model 3 β± SE 95%CI p
HADS-D 1.107 ± 0.197 0.691–1.462 < .001 HADS-D 0.914 ± 0.263 0.397–1.430 .0005
COPD Group −14.15 ± 2.24 −18.55–−9.752 < .001 COPD Group −15.10 ± 2.415 −19.83–−10.36 < .001
HADS-D by COPD Group Interaction 0.380 ± 0.413 −0.430–1.19 .358
Model 2 β± SE 95%CI p Model 4 β± SE 95%CI p
HADS-A 0.780 ± 0.170 0.446–1.114 < .001 HADS-A 0.528 ± 0.227 0.085–0.973 .0196
COPD Group −14.83 ± 2.251 −19.25–−10.42 < .001 COPD Group −17.04 ± 2.604 −22.15–−11.94 < .001
HADS-A by COPD Group Interaction 0.558 ± 0.337 −0.102–1.218 .0975
Note: All analyses adjusted for sex, age, BMI and GOLD stage. HADS-D=Depression Score from the Hospital Anxiety Depression Scale; HADS-A=Anxiety Score
from the Hospital Anxiety Depression Scale.
Fig. 1. Illustrating the relationships between smoking volume (pack years) and anxiety (left) and depression (right).
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exacerbation or symptoms. This may lead to PA avoidance in both
COPD and those with pre-clinical symptoms. This would lead to further
deconditioning, avoidance of rehab, and worse outcomes [9,10]. Taken
together, these results highlight the importance of developing health
behaviour change interventions that are flexible enough to allow for
adaptation in patients who experience high levels of psychological
distress, which are important determinants of health risk behaviours.
Another interesting question that arises from these results is whe-
ther clinicians and researchers should aim to treat the symptoms of
psychological distress or the health behaviour first. It appears that in
the case of PA, it may be possible to focus on improving the behaviour
first, given that increases in PA can lead to reduced psychological
Table 4
Impact of depression and anxiety on physical activity (PA) levels.
MAIN EFFECTS: All PA INTERACTION EFFECTS: All PA
Model 1 β± SE 95%CI p Model 3 β± SE 95%CI p
HADS-D −0.220 ± 0.028 −0.275–−0.165 < .001 HADS-D −0.232 ± 0.037 −0.304–−0.159 < .001
COPD Group 0.135 ± 0.309 −0.471–0.742 .66 COPD Group 0.069 ± 0.338 −0.595–0.732 .84
HADS-D by COPD Group Interaction 0.027 ± 0.057 −0.084–0.138 .64
Model 2 β± SE 95%CI p Model 4 β± SE 95%CI p
HADS-A −0.091 ± 0.025 −0.139–−0.043 .0002 HADS-A −0.097 ± 0.033 −0.161–−0.032 .0035
COPD Group 0.290 ± 0.314 −0.326–0.905 .36 COPD Group 0.241 ± 0.366 −0.475–0.957 .51
HADS-A by COPD Group Interaction 0.012 ± 0.050 −0.084–0.108 .80
Note: All analyses adjusted for sex, age, BMI and GOLD stage. HADS-D=Depression Score from the Hospital Anxiety Depression Scale; HADS-A=Anxiety Score
from the Hospital Anxiety Depression Scale.
Fig. 2. Illustrating the relationships between all physical activity and anxiety (left) and depression (right).
Fig. 3. Illustrating the relationships between moderate physical activity and anxiety (left) and depression (right).
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distress in patients with [36] and without [37] clinical levels of de-
pression and anxiety. Similarly, reductions in smoking can also lead to
reductions in psychological distress [38], but as depression severity is
related to the likelihood of cessation success [38], there may be a need
to treat the psychological distress in parallel with smoking cessation.
The addition of psychosocial support to smoking cessation interventions
has been shown to increase long-term cessation rates in smokers with
depression in contrast to smoking cessation alone [39]. However, the
question of what to treat first (psychological distress versus health risk
behaviours) to optimize behavioural and clinical outcomes clearly re-
quires further investigation.
Interestingly, we did not see an interaction between psychological
distress levels and COPD status for either smoking behaviours or PA,
which would suggest the magnitude and direction of these relationships
are seen in both patients with and at risk for COPD. Given that smoking
is a risk factor for COPD, the presence of depression/anxiety in patients
at risk for COPD could lead to an accelerated progression to COPD due
to higher smoking rates in this subgroup of patients. Our results provide
further support for the notion that depression and anxiety are potential
risk factors for COPD development. However, as our analysis is only
cross-sectional, we are unable to determine the temporal association
between psychological distress, health behaviours, and COPD onset.
Nonetheless, our results suggest that early identification high levels of
psychological distress may lead to early intervention and improved
outcomes.
We did not observe any interactions between depression and anxiety
for either smoking volume or for any measure of PA. This suggests that
there might not be a cumulative worsening of health behaviours with
high levels of comorbid anxiety and depression, nor is there a differ-
ential effect of depression and anxiety on smoking and PA. However,
while for smoking we did observe comparable main effects of depres-
sion and anxiety when both measures were included in our regression
analysis (as reported in Table 5), for PA we observed a main effect of
depression and no longer a main effect for anxiety. This would seem to
suggest that depression may be of greater importance in determining
PA than anxiety, but this needs further investigation.
There are some limitations regarding the study design that should
be acknowledged. As we are examining data from the baseline assess-
ments of the CanCOLD study, data are cross-sectional so we are unable
to determine the temporal association between depression/anxiety and
poor health behaviours. Future research should examine the bi-direc-
tional relationships between these variables using longitudinal designs.
We are also unable to link the observed relationships to an increased
risk of exacerbations and hospitalisations in patients with COPD. This
too represents an important avenue for future research.
Despite these limitations, this study also has several notable
strengths. First, this study includes a large sample of very well char-
acterized participants, providing a unique opportunity to compare both
Table 5
Impact of depression and anxiety on moderate physical activity (PA) levels.
MAIN EFFECTS: Moderate PA INTERACTION EFFECTS: Moderate PA
Model 1 β± SE 95%CI p Model 3 β± SE 95%CI p
HADS-D −0.176 ± 0.022 −0.219–−0.134 < .001 HADS-D −0.184 ± 0.029 −0.240–−0.127 < .001
COPD Group 0.226 ± 0.241 −0.247–0.699 .35 COPD Group 0.181 ± 0.264 −0.337–0.699 .49
HADS-D by COPD Group Interaction 0.018 ± 0.044 −0.068–0.104 .68
Model 2 β± SE 95%CI p Model 4 β± SE 95%CI p
HADS-A −0.073 ± 0.019 −0.111–−0.036 < .001 HADS-A −0.010 ± 0.026 −0.120–−0.020 .0063
COPD Group 0.349 ± 0.245 −0.132–0.830 .15 COPD Group 0.376 ± 0.258 −0.183–0.936 .188
HADS-A by COPD Group Interaction −0.007 ± 0.038 −0.081–0.067 .86
Note: All analyses adjusted for sex, age, BMI and GOLD stage. HADS-D=Depression Score from the Hospital Anxiety Depression Scale; HADS-A=Anxiety Score
from the Hospital Anxiety Depression Scale.
Table 6
Interactions between depression and anxiety on health behaviours.
MAIN EFFECTS: Pack Years INTERACTION EFFECTS: Pack Years
Model 1 β± SE 95%CI p Model 2 β±SE 95%CI p
HADS-D 0.832 ± 0.232 0.377–1.288 .0003 HADS-D 0.804 ± 0.344 0.129–1.479 .0197
HADS-A 0.405 ± 0.201 0.012–0.798 .0435 HADS-A 0.385 ± 0.268 −0.141–0.91 .15
HADS-D by HADS-A Interaction 0.005 ± 0.045 −0.083–0.093 .91
MAIN EFFECTS: All PA INTERACTION EFFECTS: All PA
Model 1 β± SE 95%CI p Model 2 β± SE 95%CI p
HADS-D −0.227 ± 0.033 −0.291–−0.163 < .001 HADS-D −0.279 ± 0.049 −0.375–−0.183 < .001
HADS-A 0.011 ± 0.028 −0.045–0.067 .69 HADS-A −0.025 ± 0.038 −0.010–0.049 .51
HADS-D by HADS-A Interaction 0.009 ± 0.006 −0.003–0.022 .15
MAIN EFFECTS: Moderate PA INTERACTION EFFECTS: Moderate PA
Model 1 β± SE 95%CI p Model 2 β± SE 95%CI p
HADS-D −0.181 ± 0.025 −0.231–−0.131 < .001 HADS-D −0.223 ± 0.038 −0.297–−0.148 < .001
HADS-A 0.009 ± 0.022 −0.035–0.052 .70 HADS-A −0.020 ± 0.030 −0.078–0.038 .50
HADS-D by HADS-A Interaction 0.007 ± 0.005 −0.003–0.017 .15
Note: All analyses adjusted for sex, age, BMI, GOLD stage and COPD Group. HADS-D=Depression Score from the Hospital Anxiety Depression Scale; HADS-
A=Anxiety Score from the Hospital Anxiety Depression Scale.
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COPD and non-COPD patients. Similarly, we used the HADS ques-
tionnaire to determine depression and anxiety symptoms, which has
excellent psychometric properties and has been used in several previous
studies of COPD cohorts. It has also been shown to be a potentially
reliable screening tool when using cut-off scores of 8 or higher on each
of the subscales [16]. However, caution is warranted as these cut-offs
may underestimate rates of depression in COPD patients [40].
In conclusion, this is the first study to show significant and im-
portant relationships between high levels of psychological distress
(depression, anxiety) and both higher smoking rates and lower PA le-
vels in individuals with and at risk for COPD. This provides support for
the hypothesis that psychological distress, via its association with two
key health behaviours important for COPD development and treatment,
may plays an important role in COPD management. Future studies are
needed to determine if treating psychological distress can improve
health behaviours and in turn, result in more favourable outcomes in
this population.
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